Alto Neuroscience Inc (ANRO) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Alto Neuroscience Inc (ANRO) following the 2026 Q2 hedge fund 13F filings?

As of today, ANRO has moved +12.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to +5.0% for the XLV sector ETF — an outperformance of +7.8%. Since the quarter end (June 30, 2026), ANRO gained +37.4% vs +10.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Alto Neuroscience Inc (ANRO)

112 + Investors. Track Smart Money conviction in ANRO. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ANRO

Based on 114 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added ANRO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

114 hedge funds hold ANRO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +44% more funds vs a year ago

fund count last 6Q

+35 new funds entered over the past year (+44% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 56% buying

67 buying52 selling

Last quarter: 67 funds bought or added vs 52 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~28 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 8 → 30 → 23 → 28. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

📌

Mixed — 29% long-term, 33% new

■ 29% conviction (2yr+) ■ 38% medium ■ 33% new

Of the 114 current holders: 33 (29%) held >2 years, 43 held 1–2 years, and 38 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💰

Value +27% but shares only +8% — price-driven

Value

+26%

+7%

Last quarter: the total dollar value of institutional holdings rose +27%, but actual share count only changed +8%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

19 → 8 → 30 → 23 → 28 new funds/Q

New funds entering each quarter: 8 → 30 → 23 → 28. A growing number of institutions are discovering ANRO each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

📊

Mixed cohorts — 27% veterans, 34% new entrants

■ 27% veterans ■ 39% 1-2yr ■ 34% new

Of 116 current holders: 31 (27%) held 2+ years, 45 held 1–2 years, 40 (34%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 24% AUM from major funds

24% from top-100 AUM funds

36 of 112 holders rank in the top 100 by AUM, accounting for 24% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.5

out of 10

Moderate Exit Risk

Exit risk score 4.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	112	110	1.82%
13F Shares	30M	27M	7.65%
Total Value	$769M	$606M	26.86%
New Positions	28	23	+5
Increased Positions	38	28	+10
Closed Positions	24	11	+13
Reduced Positions	28	42	-14
Total Calls	3	3	-
Total Puts	1	1	-
PUT/CALL Ratio	0.33	0.33	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

112

110

1.82%

13F Shares

30M

27M

7.65%

Total Value

$769M

$606M

26.86%

New Positions

Increased Positions

+10

Closed Positions

+13

Reduced Positions

-14

Total Calls

Total Puts

PUT/CALL Ratio

0.33

Bullish

Institutional Holders (2026 Q2)

112 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ANRO. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ANRO holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	72 Investment Holdings, LLC	35.27%	667,778	$17.6M
2	Spruce Street Capital LP	7.01%	1,353,047	$35.7M
3	Commodore Capital LP	4.28%	2,723,196	$71.9M
4	Vivo Capital, LLC	2.91%	1,208,858	$31.9M
5	Alpha Wave Global, LP	1.57%	3,707,757	$97.8M
6	Parkman Healthcare Partners LLC	1.16%	429,035	$11.3M
7	Ikarian Capital, LLC	1.16%	407,338	$10.7M
8	Affinity Asset Advisors, LLC	1.01%	850,000	$22.4M
9	Saturn V Capital Management LP	0.69%	182,829	$4.8M
10	Perceptive Advisors LLC	0.64%	1,609,893	$42.5M
11	Integral Health Asset Management, LLC	0.52%	500,000	$13.2M
12	Vestal Point Capital, LP	0.48%	785,000	$20.7M
13	Venrock Adviser, LLC	0.40%	500,000	$13.2M
14	Armistice Capital, LLC	0.28%	864,000	$22.8M
15	AdvisorShares Investments LLC	0.23%	70,748	$1.9M
16	AWM Investment Company, Inc.	0.18%	80,000	$2.1M
17	Eversept Partners, LP	0.18%	128,286	$3.4M
18	Orbimed Advisors LLC	0.13%	257,852	$6.8M
19	GK Wealth Management LLC	0.12%	8,565	$226K
20	Revisor Wealth Management LLC	0.11%	17,130	$452K
21	Virtus Investment Advisers, LLC	0.09%	15,239	$402K
22	Driehaus Capital Management LLC	0.07%	487,576	$12.9M
23	University of Texas/Texas AM Investment Management Co	0.07%	22,175	$585K
24	Persistent Asset Partners Ltd	0.06%	7,698	$203K
25	Adage Capital Partners GP, L.L.C.	0.06%	1,600,000	$42.2M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Alto Neuroscience Inc (ANRO)

What does the Smart Money Trend signal show for ANRO?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added ANRO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ANRO?

Slight buying edge — 56% buying: Last quarter: 67 funds bought or added vs 52 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ANRO holders?

Strong quality — 24% AUM from major funds: 36 of 112 holders rank in the top 100 by AUM, accounting for 24% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ANRO?

Mixed — 29% long-term, 33% new: Of the 114 current holders: 33 (29%) held >2 years, 43 held 1–2 years, and 38 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Alto Neuroscience Inc (ANRO) following the 2026 Q2 hedge fund 13F filings?

As of today, ANRO has moved +12.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to +5.0% for the XLV sector ETF — an outperformance of +7.8%. Since the quarter end (June 30, 2026), ANRO has gained +37.4% vs +10.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Alto Neuroscience Inc (ANRO)

Smart Money Signals — ANRO

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +44% more funds vs a year ago

Slight buying edge — 56% buying

Steady new buyers — ~28 new funds per quarter

Mixed — 29% long-term, 33% new

Value +27% but shares only +8% — price-driven

Growing discovery — still being found

Mixed cohorts — 27% veterans, 34% new entrants

Strong quality — 24% AUM from major funds

Institutional Sentiment Summary — ANRO

Hedge Fund Ownership: ANRO

Market Analysis: ANRO

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ANRO

Is It Too Late to Buy Alto Neuroscience Inc (ANRO) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ANRO

Statistics: ANRO

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Alto Neuroscience Inc (ANRO)

Welcome to 13Foresight!